Opinion

Palovarotene is the first medicine to be submitted for regulatory approval for fibrodysplasia ossificans progressiva (FOP), an ultra-rare disease with an estimated prevalence of 1.36 per million individuals and around 900 people diagnosed…

If approved for Europe, PYLCLARI® (INN: Piflufolastat (18F) formerly known as -DCFPyL) will offer prostate cancer patients access to a diagnostic imaging agent more sensitive than conventional imaging.Proven track record of -DCFPyL…

…

Decision ends nearly decade-long patent dispute related to…

The webinar will take place on Wednesday, May 10, 2023 at 1:00 PM…

Event on May 22nd will feature Elias Reichel, M.D., Professor,…

Company to provide a detailed overview of its norovirus clinical…

<!-- Name:DistributionId Value:8783305 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4530 -->…

<!-- Name:DistributionId Value:8756345 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4577 -->…

Tibsovo® (ivosidenib tablets) is the first IDH1 inhibitor recommended for approval in EuropeThe positive CHMP opinion is based on clinical data from the AGILE (in AML) and ClarIDHy (in CCA) studiesPARIS, Feb. 24, 2023 /PRNewswire/ --…